Title |
Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
|
---|---|
Published in |
Frontiers in Medicine, August 2017
|
DOI | 10.3389/fmed.2017.00142 |
Pubmed ID | |
Authors |
Alannah Smrke, Peter L. Gross |
Abstract |
Patients with cancer are at significantly higher risk of developing, and dying from, venous thromboembolism (VTE). The CLOT trial demonstrated superiority of low-molecular-weight heparins (LMWH) over warfarin for recurrent VTE and established LMWH as the standard of care for cancer-associated VTE. However, with patients living longer with metastatic cancer, long-term injections are associated with significant cost and injection fatigue. Direct oral anticoagulants (DOACs) are an attractive alternative for treatment of cancer-associated VTE. Meta-analysis of subgroup data of patients with cancer from the large DOAC VTE trials and small non-randomized studies have found no difference in VTE recurrence or major bleeding. With this limited evidence, clinicians may decide to switch their patients who require long-term anticoagulation from LMWH to a DOAC. This requires careful consideration of the interplay between the patient's cancer and treatment course, with their underlying comorbidities. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Saudi Arabia | 1 | 25% |
Spain | 1 | 25% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 53 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 7 | 13% |
Other | 6 | 11% |
Student > Bachelor | 5 | 9% |
Researcher | 5 | 9% |
Student > Doctoral Student | 4 | 8% |
Other | 12 | 23% |
Unknown | 14 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 43% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Nursing and Health Professions | 2 | 4% |
Agricultural and Biological Sciences | 1 | 2% |
Other | 2 | 4% |
Unknown | 18 | 34% |